Sabra Health Care REIT, Inc.

NasdaqGS:SBRA Stock Report

Market Cap: US$4.0b

Sabra Health Care REIT Valuation

Is SBRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SBRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SBRA ($16.96) is trading below our estimate of fair value ($33.82)

Significantly Below Fair Value: SBRA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SBRA?

Key metric: As SBRA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SBRA. This is calculated by dividing SBRA's market cap by their current earnings.
What is SBRA's PE Ratio?
PE Ratio41.3x
EarningsUS$97.17m
Market CapUS$4.01b

Price to Earnings Ratio vs Peers

How does SBRA's PE Ratio compare to its peers?

The above table shows the PE ratio for SBRA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38.1x
CTRE CareTrust REIT
51.9x45.0%US$5.1b
NHI National Health Investors
25x10.8%US$3.2b
LTC LTC Properties
15.8x-4.7%US$1.6b
SILA Sila Realty Trust
59.7x11.5%US$1.3b
SBRA Sabra Health Care REIT
41.3x18.9%US$4.0b

Price-To-Earnings vs Peers: SBRA is expensive based on its Price-To-Earnings Ratio (41.3x) compared to the peer average (38.1x).

Price to Earnings Ratio vs Industry

How does SBRA's PE Ratio compare vs other companies in the Global Health Care REITs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
SBRA 41.3xIndustry Avg. 24.9xNo. of Companies5PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SBRA is expensive based on its Price-To-Earnings Ratio (41.3x) compared to the Global Health Care REITs industry average (24.9x).

Price to Earnings Ratio vs Fair Ratio

What is SBRA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SBRA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio41.3x
Fair PE Ratio40.3x

Price-To-Earnings vs Fair Ratio: SBRA is expensive based on its Price-To-Earnings Ratio (41.3x) compared to the estimated Fair Price-To-Earnings Ratio (40.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SBRA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$16.96
US$20.00
+17.9%
6.4%US$21.00US$18.00n/a11
Dec ’25US$18.73
US$19.59
+4.6%
6.6%US$21.00US$18.00n/a11
Nov ’25US$18.64
US$19.05
+2.2%
7.1%US$21.00US$16.00n/a11
Oct ’25US$18.58
US$18.77
+1.0%
7.6%US$21.00US$16.00n/a11
Sep ’25US$17.04
US$17.45
+2.4%
9.3%US$21.00US$15.00n/a10
Aug ’25US$16.16
US$16.41
+1.6%
10.9%US$21.00US$14.00n/a11
Jul ’25US$15.41
US$16.18
+5.0%
10.8%US$21.00US$14.00n/a11
Jun ’25US$14.58
US$16.09
+10.4%
11.1%US$21.00US$14.00n/a11
May ’25US$13.93
US$15.91
+14.2%
12.1%US$21.00US$14.00n/a11
Apr ’25US$14.71
US$15.91
+8.2%
12.1%US$21.00US$14.00n/a11
Mar ’25US$13.99
US$15.92
+13.8%
11.6%US$21.00US$14.00n/a12
Feb ’25US$13.44
US$15.92
+18.4%
11.6%US$21.00US$14.00n/a12
Jan ’25US$14.27
US$15.27
+7.0%
4.9%US$16.00US$14.00n/a11
Dec ’24US$14.67
US$14.92
+1.7%
7.5%US$16.00US$13.00US$18.7312
Nov ’24US$13.92
US$14.63
+5.1%
8.5%US$16.00US$12.50US$18.6412
Oct ’24US$13.94
US$13.79
-1.1%
6.2%US$15.00US$12.50US$18.5812
Sep ’24US$12.93
US$13.21
+2.2%
7.2%US$15.00US$11.00US$17.0412
Aug ’24US$12.94
US$12.71
-1.8%
9.2%US$15.00US$11.00US$16.1612
Jul ’24US$11.77
US$12.55
+6.6%
10.4%US$15.00US$11.00US$15.4111
Jun ’24US$11.15
US$12.58
+12.9%
10.0%US$15.00US$11.00US$14.5812
May ’24US$11.36
US$12.68
+11.6%
12.2%US$15.00US$10.50US$13.9311
Apr ’24US$11.50
US$13.14
+14.2%
12.2%US$15.00US$10.50US$14.7111
Mar ’24US$11.80
US$13.71
+16.2%
8.7%US$15.00US$11.00US$13.9912
Feb ’24US$13.52
US$14.08
+4.1%
10.2%US$18.00US$12.00US$13.4413
Jan ’24US$12.43
US$14.38
+15.7%
10.4%US$18.00US$12.00US$14.2713
Dec ’23US$12.82
US$14.84
+15.8%
10.9%US$18.00US$12.00US$14.6714

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:37
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sabra Health Care REIT, Inc. is covered by 33 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RodgersBaird
Amanda SweitzerBaird
Joshua RaskinBarclays